Annalise.ai vs Rayscape
Two comprehensive chest radiograph platforms, both claiming to read for a very large number of findings, and the comparison should not be run on that number. Annalise is the more established, operating as a joint venture with a large radiology provider and carrying regulatory footprints across multiple markets. Rayscape is smaller and has the more interesting evidence: independent evaluation in a tuberculosis screening setting, which is a harder test than a reader study because the deployment is exactly where radiologist capacity is thinnest and the consequence of a miss is highest. It also adds longitudinal comparison across prior scans and offers on premise deployment. For a hospital standardising across sites, Annalise carries fewer unknowns. For a screening programme, Rayscape has been tested in something resembling the real conditions.
- The evidence includes independent evaluation in a tuberculosis screening context, which is a harder and more consequential test than a retrospective reader study.
- Findings breadth on chest radiography is substantial and the platform adds longitudinal comparison across a patient's prior scans, so change over time is visible rather than each study read in isolation.
- Both on premise and cloud integration are offered, which matters where images cannot leave the institution or the country.
- The comprehensive chest radiograph position is established across a large findings set with regulatory footprints in multiple markets, backed by a joint venture with a large radiology provider that supplies real reading volume.
- Deployment maturity is greater, which matters for a modality where the failure mode is a subtle finding missed at scale rather than a dramatic error.
- For a health system standardising chest radiograph AI across sites, the more widely deployed platform carries fewer unknowns.
Side by Side
| Axis | A Annalise.ai |
R Rayscape |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Comprehensive chest radiograph products claim large numbers of findings and those numbers are not comparable across vendors, because each counts differently and the per finding performance varies enormously within any such list. Ask both for performance on the specific findings that matter in your population rather than for the headline count. Neither vendor publishes a security attestation or trust centre.
Prevalence is the other uncontrolled variable: a model validated in a high tuberculosis burden setting will produce very different positive predictive values in a low prevalence one, and neither vendor publishes performance stratified that way.